Cargando…

In Vitro Assessment of the Genotoxic Hazard of Novel Hydroxamic Acid- and Benzamide-Type Histone Deacetylase Inhibitors (HDACi)

Histone deacetylase inhibitors (HDACi) are already approved for the therapy of leukemias. Since they are also emerging candidate compounds for the treatment of non-malignant diseases, HDACi with a wide therapeutic window and low hazard potential are desirable. Here, we investigated a panel of 12 nov...

Descripción completa

Detalles Bibliográficos
Autores principales:	Friedrich, Annabelle, Assmann, Ann-Sophie, Schumacher, Lena, Stuijvenberg, Jana v., Kassack, Matthias U., Schulz, Wolfgang A., Roos, Wynand P., Hansen, Finn K., Pflieger, Marc, Kurz, Thomas, Fritz, Gerhard
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7370100/ https://www.ncbi.nlm.nih.gov/pubmed/32635356 http://dx.doi.org/10.3390/ijms21134747

Ejemplares similares

Role of Hydroxamate-Based Histone Deacetylase Inhibitors (Hb-HDACIs) in the Treatment of Solid Malignancies
por: Grassadonia, Antonino, et al.
Publicado: (2013)

Histone deacetylase inhibitors (HDACIs): multitargeted anticancer agents
por: Ververis, Katherine, et al.
Publicado: (2013)

HDACiDB: a database for histone deacetylase inhibitors
por: Murugan, Kasi, et al.
Publicado: (2015)

Combination Therapy With Histone Deacetylase Inhibitors (HDACi) for the Treatment of Cancer: Achieving the Full Therapeutic Potential of HDACi
por: Suraweera, Amila, et al.
Publicado: (2018)

Histone Deacetylase Inhibitors (HDACi) Cause the Selective Depletion of Bromodomain Containing Proteins (BCPs)
por: Mackmull, Marie-Therese, et al.
Publicado: (2015)

Non-Hydroxamate Zinc-Binding Groups as Warheads for Histone Deacetylases
por: Frühauf, Anton, et al.
Publicado: (2021)

Development of Coumarin-Based Hydroxamates as Histone Deacetylase Inhibitors with Antitumor Activities
por: Zhao, Na, et al.
Publicado: (2020)

Histone Deacetylase Inhibitors (HDACi) Promote KLF5 Ubiquitination and Degradation in Basal-like Breast Cancer
por: Kong, Yanjie, et al.
Publicado: (2022)

Histone deacetylase inhibitor LMK235 attenuates vascular constriction and aortic remodelling in hypertension
por: Choi, Sin Young, et al.
Publicado: (2019)

The Histone Deacetylase Inhibitor Suberoylanilide Hydroxamic Acid Alleviates Salinity Stress in Cassava
por: Patanun, Onsaya, et al.
Publicado: (2017)

Selectivity of Hydroxamate- and Difluoromethyloxadiazole-Based Inhibitors of Histone Deacetylase 6 In Vitro and in Cells
por: Ptacek, Jakub, et al.
Publicado: (2023)

HDACi Valproic Acid (VPA) and Suberoylanilide Hydroxamic Acid (SAHA) Delay but Fail to Protect against Warm Hepatic Ischemia-Reperfusion Injury
por: Ruess, Dietrich A., et al.
Publicado: (2016)

Natural Compound Histone Deacetylase Inhibitors (HDACi): Synergy with Inflammatory Signaling Pathway Modulators and Clinical Applications in Cancer
por: Losson, Hélène, et al.
Publicado: (2016)

The multifaceted influence of histone deacetylases on DNA damage signalling and DNA repair
por: Roos, Wynand Paul, et al.
Publicado: (2016)

Ron Knockdown and Ron Monoclonal Antibody IMC-RON8 Sensitize Pancreatic Cancer to Histone Deacetylase Inhibitors (HDACi)
por: Zou, Yi, et al.
Publicado: (2013)

DDEL-10. A NANOPARTICLE PLATFORM FOR INTRATHECAL DELIVERY OF THE HISTONE DEACETYLASE INHIBITOR (HDACi) PANOBINOSTAT IN METASTATIC OR RECURRENT MEDULLOBLASTOMA
por: Chaudhuri, Sauradip, et al.
Publicado: (2020)

Hydroxamic acid-modified peptide microarrays for profiling isozyme-selective interactions and inhibition of histone deacetylases
por: Moreno-Yruela, Carlos, et al.
Publicado: (2021)

Chromatin remodeling induced by histone deacetylase inhibitors (HDACis) in HeLa, NIH 3T3 and HepG2 cells
por: Felisbino, Marina B, et al.
Publicado: (2013)

Evaluation of the antioxidant effects of different histone deacetylase inhibitors (HDACis) on human lens epithelial cells (HLECs) after UVB exposure
por: Qiu, Xiaodi, et al.
Publicado: (2019)

A transcriptomic dataset used to derive biomarkers of chemically induced histone deacetylase inhibition (HDACi) in human TK6 cells
por: Cho, Eunnara, et al.
Publicado: (2021)

FOXA1 Regulation Turns Benzamide HDACi Treatment Effect-Specific in BC, Promoting NIS Gene-Mediated Targeted Radioiodine Therapy
por: Rathod, Maitreyi, et al.
Publicado: (2020)

Clinical experience with the novel histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid) in patients with relapsed lymphoma
por: O'Connor, O A
Publicado: (2006)

In silico modification of suberoylanilide hydroxamic acid (SAHA) as potential inhibitor for class II histone deacetylase (HDAC)
por: Tambunan, Usman SF, et al.
Publicado: (2011)

The histone deacetylase inhibitor suberoylanilide hydroxamic acid attenuates human astrocyte neurotoxicity induced by interferon-γ
por: Klegeris, Andis, et al.
Publicado: (2012)

Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor, attenuates postoperative cognitive dysfunction in aging mice
por: Jia, Min, et al.
Publicado: (2015)

A Novel Hydroxamic Acid-Based Curcumin Derivative as Potent Histone Deacetylase Inhibitor for the Treatment of Glioblastoma
por: Wang, Hao, et al.
Publicado: (2021)

1,3-Diphenylureido hydroxamate as a promising scaffold for generation of potent antimalarial histone deacetylase inhibitors
por: Tavares, Maurício T., et al.
Publicado: (2023)

HDACIs and the inhibition of invasive potential
por: Dent, Paul
Publicado: (2013)

Sodium Butyrate Enhances the Cytotoxic Effect of Etoposide in HDACi-Sensitive and HDACi-Resistant Transformed Cells
por: Gnedina, Olga O., et al.
Publicado: (2023)

Cancer biology: mechanism of antitumour action of vorinostat (suberoylanilide hydroxamic acid), a novel histone deacetylase inhibitor
por: Richon, V M
Publicado: (2006)

Hydroxamic Acid-Based Histone Deacetylase (HDAC) Inhibitors Bearing a Pyrazole Scaffold and a Cinnamoyl Linker
por: Zagni, Chiara, et al.
Publicado: (2019)

Hydroxamic Acids Immobilized on Resins (HAIRs): Synthesis of Dual‐Targeting HDAC Inhibitors and HDAC Degraders (PROTACs)
por: Sinatra, Laura, et al.
Publicado: (2020)

The Role of HDACs and HDACi in Cartilage and Osteoarthritis
por: Zhang, He, et al.
Publicado: (2020)

The Novel Class IIa Selective Histone Deacetylase Inhibitor YAK540 Is Synergistic with Bortezomib in Leukemia Cell Lines
por: Bollmann, Lukas M., et al.
Publicado: (2022)

Utilization of Boron Compounds for the Modification of Suberoyl Anilide Hydroxamic Acid as Inhibitor of Histone Deacetylase Class II Homo sapiens
por: Bakri, Ridla, et al.
Publicado: (2014)

Suberoylanilide Hydroxamic Acid, an Inhibitor of Histone Deacetylase, Enhances Radiosensitivity and Suppresses Lung Metastasis in Breast Cancer In Vitro and In Vivo
por: Chiu, Hui-Wen, et al.
Publicado: (2013)

Subchronic Toxicities of HZ1006, a Hydroxamate-Based Histone Deacetylase Inhibitor, in Beagle Dogs and Sprague-Dawley Rats
por: Zhang, Xiaofang, et al.
Publicado: (2016)

The Histone Deacetylase Inhibitor Suberoylanilide Hydroxamic Acid (SAHA) Restores Cardiomyocyte Contractility in a Rat Model of Early Diabetes
por: Bocchi, Leonardo, et al.
Publicado: (2019)

Design, Synthesis and Biological Evaluation of Novel Coumarin-Based Hydroxamate Derivatives as Histone Deacetylase (Hdac) Inhibitors with Antitumor Activities
por: Yang, Feifei, et al.
Publicado: (2019)

Synergistic effects of combined treatment with histone deacetylase inhibitor suberoylanilide hydroxamic acid and TRAIL on human breast cancer cells
por: Zhou, Weiqiang, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_crh7e312di7avgcpfhmgel4huv